Lenalidomide Zentiva (Lenalidomide)

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related bone‑marrow disorders.

• Multiple myeloma: improves disease control, prolongs progression‑free and overall survival.
• Myelodysplastic syndromes with 5q deletion: reduces transfusion dependence and ameliorates cytopenias.

• Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting degradation of transcription factors such as Ikaros and Aiolos. This modulates cytokine production, inhibits angiogenesis, and enhances T‑ and NK‑cell mediated immune responses, leading to apoptosis of malignant plasma cells and clonal myeloid cells.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count leading to infection risk.
• Thrombocytopenia: low platelet levels causing bleeding tendency.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: gastrointestinal upset often mild.
• Diarrhea: loose stools, may lead to dehydration.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: marked infection risk requiring hospitalization.
• Severe thrombocytopenia: significant bleeding events.
• Secondary primary malignancies: emergence of new cancers.
• Stevens‑Johnson syndrome: severe skin reaction with mucosal involvement.
• Hepatic failure: marked liver enzyme elevation and dysfunction.

Before initiating Lenalidomide therapy, several precautionary measures should be observed to ensure patient safety.

• Pregnancy contraindication: drug is teratogenic; avoid use in pregnancy and ensure effective contraception.
• Thrombosis risk: assess for history of clotting disorders and consider prophylactic anticoagulation.
• Hematologic monitoring: perform regular complete blood counts to detect cytopenias.
• Renal impairment: adjust dose in patients with reduced kidney function.
• Drug interaction vigilance: review concomitant medications that affect CYP3A4 metabolism.
• Store at below 25°C: keep in original container, protect from moisture and light.

Lenalidomide interacts with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lenalidomide exposure, raising toxicity risk.
• Strong CYP3A4 inducers (e.g., rifampin, phenytoin): decrease drug levels, reducing efficacy.
• Thalidomide co‑administration: heightened risk of peripheral neuropathy and thromboembolic events.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, direct oral anticoagulants): may amplify bleeding risk; monitor coagulation parameters.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal toxicity.
• Live vaccines: immune response may be diminished; avoid during therapy.